SHANGHAI FUDAN H YC-,10 (FDY) - Net Assets
Based on the latest financial reports, SHANGHAI FUDAN H YC-,10 (FDY) has net assets worth €2.15 Billion EUR (≈ $2.52 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.41 Billion ≈ $2.82 Billion USD) and total liabilities (€260.40 Million ≈ $304.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See FDY net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.15 Billion |
| % of Total Assets | 89.21% |
| Annual Growth Rate | -0.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.01 |
SHANGHAI FUDAN H YC-,10 - Net Assets Trend (2021–2025)
This chart illustrates how SHANGHAI FUDAN H YC-,10's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see SHANGHAI FUDAN H YC-,10 market capitalisation.
Annual Net Assets for SHANGHAI FUDAN H YC-,10 (2021–2025)
The table below shows the annual net assets of SHANGHAI FUDAN H YC-,10 from 2021 to 2025. Also explore SHANGHAI FUDAN H YC-,10 equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.12 Billion ≈ $2.47 Billion |
-8.18% |
| 2024-12-31 | €2.31 Billion ≈ $2.70 Billion |
-2.26% |
| 2023-12-31 | €2.36 Billion ≈ $2.76 Billion |
+4.68% |
| 2022-12-31 | €2.25 Billion ≈ $2.63 Billion |
+2.90% |
| 2021-12-31 | €2.19 Billion ≈ $2.56 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SHANGHAI FUDAN H YC-,10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €676.22 Million | 31.95% |
| Other Components | €1.44 Billion | 68.05% |
| Total Equity | €2.12 Billion | 100.00% |
SHANGHAI FUDAN H YC-,10 Competitors by Market Cap
The table below lists competitors of SHANGHAI FUDAN H YC-,10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Reform Culture Holdings Co Ltd
SHG:600636
|
$109.76 Million |
|
Sat Industries Limited
NSE:SATINDLTD
|
$109.77 Million |
|
Union Bankshares Inc
NASDAQ:UNB
|
$109.79 Million |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
$109.81 Million |
|
Indústrias Romi S.A
SA:ROMI3
|
$109.69 Million |
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
$109.68 Million |
|
SINGULAR PEOPLE S EO-1
F:H0U
|
$109.66 Million |
|
Tongyang
KO:001520
|
$109.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANGHAI FUDAN H YC-,10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,304,567,412 to 2,116,293,902, a change of -188,273,510 (-8.2%).
- Net loss of 157,439,498 reduced equity.
- Dividend payments of 31,097,163 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-157.44 Million | -7.44% |
| Dividends Paid | €31.10 Million | -1.47% |
| Other Changes | €263.15K | +0.01% |
| Total Change | €- | -8.17% |
Book Value vs Market Value Analysis
This analysis compares SHANGHAI FUDAN H YC-,10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.14x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.10 | €0.28 | x |
| 2022-12-31 | €2.19 | €0.28 | x |
| 2023-12-31 | €2.26 | €0.28 | x |
| 2024-12-31 | €2.21 | €0.28 | x |
| 2025-12-31 | €2.03 | €0.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANGHAI FUDAN H YC-,10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.96%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.13x
- Recent ROE (-7.44%) is below the historical average (2.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 9.73% | 18.71% | 0.41x | 1.27x | €-6.00 Million |
| 2022 | 6.11% | 13.38% | 0.35x | 1.32x | €-87.71 Million |
| 2023 | 4.61% | 12.77% | 0.30x | 1.22x | €-127.13 Million |
| 2024 | 1.72% | 5.60% | 0.27x | 1.12x | €-190.72 Million |
| 2025 | -7.44% | -22.96% | 0.29x | 1.13x | €-369.07 Million |
Industry Comparison
This section compares SHANGHAI FUDAN H YC-,10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,764,249,710
- Average return on equity (ROE) among peers: -103.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANGHAI FUDAN H YC-,10 (FDY) | €2.15 Billion | 9.73% | 0.12x | $109.71 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.24 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $35.36 Billion | 15.71% | 0.13x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $252.60 Million | -46.62% | 0.59x | $123.09 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-11.28 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $6.62 Million |
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more